A Breast Cancer Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report: By Circulating Biomarkers [Circulating Tumor Cells (CTCs), Circulating Cell-Free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers]

Breast Cancer Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report: By Circulating Biomarkers [Circulating Tumor Cells (CTCs), Circulating Cell-Free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers], Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast (2025–2034)

The global breast cancer liquid biopsy market size is expected to reach USD 2,731.02 million by 2034, according to a new study by Polaris Market Research. The report “Breast Cancer Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report – By Circulating Biomarkers [Circulating Tumor Cells (CTCs), Circulating Cell-Free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers], Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The breast cancer liquid biopsy market is experiencing significant growth due to the increasing prevalence of breast cancer globally and the rising demand for noninvasive diagnostic tools. Liquid biopsy analyzes circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) from blood samples. It offers several advantages over traditional tissue biopsies, including reduced patient discomfort and the ability to monitor treatment response in real time. Advancements in molecular biology and genomics have improved liquid biopsy tests, enabling earlier detection and more precise treatment of breast cancer, further boosting market growth.

The rising awareness among healthcare professionals and patients regarding the benefits of early cancer detection is driving demand for liquid biopsy solutions. Government initiatives promoting cancer screening and research funding also play a crucial role in fostering market growth. In addition, the shift toward personalized medicine is leading to a greater emphasis on targeted therapies, making liquid biopsies an essential tool for tailoring treatments to individual patients based on their unique genetic profiles.

The presence of major biotechnology and pharmaceutical companies, coupled with robust research and development activities, is further stimulating innovation in this sector. As the healthcare landscape evolves and more providers adopt liquid biopsy technology, it improves breast cancer diagnosis and management while enhancing patient outcomes. All these factors mentioned above drive the breast cancer liquid biopsy market growth.

Breast Cancer Liquid Biopsy Market Report Highlights

Based on circulating biomarkers, in 2024, the circulating cell-free DNA (cfDNA) segment accounted for the largest revenue share in the breast cancer liquid biopsy market due to its enhanced sensitivity.

The early detection/screening segment, by application, is expected to register the highest CAGR during the forecast period due to the increasing awareness of the importance of early cancer diagnosis.

In 2024, North America accounted for the largest share of the breast cancer liquid biopsy market due to high adoption rates of innovative diagnostic technologies across the region.

The Asia Pacific market is expected to register the highest CAGR during the forecast period due to an increasing prevalence of breast cancer across the region.

A few global key market players are Biocept, Inc.; Epic Sciences, Inc.; F. Hoffmann - La Roche Ltd.; Fluxion Biosciences, Inc.; Myriad Genetics, Inc.; NeoGenomics Laboratories; QIAGEN; Sysmex Corporation; The Menarini Group; and Thermo Fisher Scientific, Inc.

Polaris Market Research has segmented the breast cancer liquid biopsy market report on the basis of circulating biomarkers, application, and region:

By Circulating Biomarkers Outlook (Revenue – USD Million, 2020–2034)

Circulating Tumor Cells (CTCs)

Circulating Cell-Free DNA (cfDNA)

Extracellular Vesicles (EVs)

Other Circulating Biomarkers

By Application Outlook (Revenue – USD Million, 2020–2034)

Early Detection/Screening

Diagnosis

Treatment Selection

Monitoring

By Regional Outlook (Revenue – USD Million, 2020–2034)

North America

• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Australia
• Rest of Asia Pacific
• Latin America
• Argentina
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of Middle East & Africa